Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/26680
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | May, Clive N | - |
dc.contributor.author | Bellomo, Rinaldo | - |
dc.contributor.author | Lankadeva, Yugeesh R | - |
dc.date | 2021-10 | - |
dc.date.accessioned | 2021-06-07T06:03:55Z | - |
dc.date.available | 2021-06-07T06:03:55Z | - |
dc.date.issued | 2021-06-01 | - |
dc.identifier.citation | British Journal of Pharmacology 2021; 178(19): 3864-3868 | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/26680 | - |
dc.description.abstract | Sepsis induced by bacteria or viruses can result in multi-organ dysfunction, which is a major cause of death in intensive care units. Current treatments are only supportive and there are no treatments that reverse the pathophysiological effects of sepsis. Vitamin C has antioxidant, anti-inflammatory, anticoagulant and immune modulatory actions, so is a rational treatment for sepsis. Here we summarise data that support the use of megadose vitamin C as a treatment for sepsis and COVID-19. Mega-dose intravenous sodium ascorbate (150 g/40 kg over 7-h) dramatically improved the clinical state and cardiovascular, pulmonary, hepatic and renal function and decreased body temperature, in a clinically relevant ovine model of gram-negative bacteria-induced sepsis. In a critically ill COVID-19 patient, intravenous sodium ascorbate (60 g) restored arterial pressure, improved renal function and increased arterial blood oxygen levels. These findings suggest that megadose vitamin C should be trialled as a treatment for sepsis and COVID-19. | en |
dc.language.iso | eng | - |
dc.subject | COVID-19 | en |
dc.subject | Sepsis | en |
dc.subject | acute kidney injury | en |
dc.subject | hypotension | en |
dc.subject | hypoxia | en |
dc.subject | inflammation | en |
dc.subject | oxidative stress | en |
dc.subject | sodium ascorbate | en |
dc.subject | vitamin C | en |
dc.title | Therapeutic potential of mega-dose vitamin C to reverse organ dysfunction in sepsis and COVID-19. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | British Journal of Pharmacology | en |
dc.identifier.affiliation | Department of Critical Care, Melbourne Medical School, University of Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Intensive Care | en |
dc.identifier.affiliation | Preclinical Critical Care Unit, Florey Institute of Neuroscience and Mental Health University of Melbourne, Victoria, Australia | en |
dc.identifier.doi | 10.1111/bph.15579 | en |
dc.type.content | Text | en |
dc.identifier.orcid | 0000-0001-8548-3846 | en |
dc.identifier.orcid | 0000-0002-3589-9111 | en |
dc.identifier.pubmedid | 34061355 | - |
local.name.researcher | Bellomo, Rinaldo | |
item.openairetype | Journal Article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | Intensive Care | - |
crisitem.author.dept | Data Analytics Research and Evaluation (DARE) Centre | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.